Trials / Completed
CompletedNCT01936844
Interleukin (IL)-1 Blockade in Acute Heart Failure (Anakinra ADHF)
Interleukin-1 Blockade in Acute Decompensated Heart Failure
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Virginia Commonwealth University · Academic / Other
- Sex
- All
- Age
- 21 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
Anakinra ADHF is a double-blind randomized clinical trial of anakinra, recombinant human interleukin-1 receptor blocker, or placebo in patients with acute decompensated heart failure with the aim to quench the acute inflammatory response, as measured by the area-under-the-curve for C reactive protein over 14 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anakinra (high dose) | Anakinra 100 mg daily twice daily for days 1, 2, and 3 |
| DRUG | Anakinra (standard dose) | Anakinra 100 mg daily for days 4-14 |
| DRUG | Placebo | Placebo twice daily for days 1, 2, and 3 |
| DRUG | Placebo | Placebo daily for days 4-14 |
Timeline
- Start date
- 2014-02-01
- Primary completion
- 2015-05-01
- Completion
- 2015-05-01
- First posted
- 2013-09-06
- Last updated
- 2016-05-05
- Results posted
- 2016-03-22
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01936844. Inclusion in this directory is not an endorsement.